Monte Rosa Therapeutics Inc 2025年度报告

Monte Rosa Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Common stock, par value $0.0001 per share Securities registered pursuant to Section 12(g) of the Act:None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES☒NO☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES☐NO☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days. YES☒NO☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submitsuch files). YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.☐If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ The number of shares of Registrant’s Common Stock outstanding as of March 2, 2026, was 80,015,667. DOCUMENTS INCORPORATED BY REFERENCE Portions of registrant's definitive proxy statement for its annual meeting of shareholders to be filed within 120 days after the close of the registrant'sfiscal year are incorporated by reference to into Part III of this annual report on Form 10-K. Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART IIItem 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities143Item 6.[Reserved]144Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations145Item 7A.Quantitative and Qualitative Disclosures About Market Risk157Item 8.Financial Statements and Supplementary Data157Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure158Item 9A.Controls and Procedures158Item 9B.Other Information158Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections159 PART IIIItem 10. Directors, Executive Officers and Corporate Governance160Item 11.Executive Compensation160Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters160Item 13.Certain Relationships and Related Transactions, and Director Independence160Item 14.Principal Accountant Fees and Services160 PART IVItem 15. Exhibits and Financial Statement Schedules161Item 16.Form 10-K Summary162 SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements which are made pursuant tothe safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the or the Securities Act, andSection 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other thanstatements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you canidentify forward-l